LAVA Therapeutics NV
LVTX
View Detailed Chart
1.740USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
45.77MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
+32.82%
Year to Date
+82.97%
1 Year
+68.93%
View Detailed Chart
TradingKey Stock Score of LAVA Therapeutics NV
Currency: USD Updated: 2025-11-21Key Insights
LAVA Therapeutics NV's fundamentals are relatively very healthy, Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at max_target_price.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.
LAVA Therapeutics NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
1.500
Target Price
-13.79%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
LAVA Therapeutics NV Highlights
StrengthsRisks
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Growing
The company is in a growing phase, with the latest annual income totaling USD 11.98M.
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 7.48M shares, decreasing 38.60% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.49.
LAVA Therapeutics NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
LAVA Therapeutics NV Info
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Ticker SymbolLVTX
CompanyLAVA Therapeutics NV
CEOMr. Stephen A. Hurly
Websitehttps://www.lavatherapeutics.com/
FAQs
What is the current price of LAVA Therapeutics NV (LVTX)?
The current price of LAVA Therapeutics NV (LVTX) is 1.740.
What is the symbol of LAVA Therapeutics NV?
The ticker symbol of LAVA Therapeutics NV is LVTX.
What is the 52-week high of LAVA Therapeutics NV?
The 52-week high of LAVA Therapeutics NV is 2.000.
What is the 52-week low of LAVA Therapeutics NV?
The 52-week low of LAVA Therapeutics NV is 0.850.
What is the market capitalization of LAVA Therapeutics NV?
The market capitalization of LAVA Therapeutics NV is 45.77M.
What is the net income of LAVA Therapeutics NV?
The net income of LAVA Therapeutics NV is -25.11M.
Is LAVA Therapeutics NV (LVTX) currently rated as Buy, Hold, or Sell?
According to analysts, LAVA Therapeutics NV (LVTX) has an overall rating of --, with a price target of 1.500.
What is the Earnings Per Share (EPS TTM) of LAVA Therapeutics NV (LVTX)?
The Earnings Per Share (EPS TTM) of LAVA Therapeutics NV (LVTX) is -0.865.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
